Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 32.0%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ4.12 K Cr | β | βΉ1.09 K Cr | β | β | 11.2% | -1.2% | 4.5% |
| Mar 2024 | βΉ4.17 K Cr | β | βΉ1.04 K Cr | β | β | 11.6% | 15.2% | 34.4% |
| Mar 2023 | βΉ3.62 K Cr | β | βΉ776.00 Cr | β | β | 9.8% | -17.8% | -36.0% |
| Mar 2022 | βΉ4.40 K Cr | β | βΉ1.21 K Cr | β | β | 16.9% | 27.1% | 21.6% |
| Mar 2021 | βΉ3.46 K Cr | β | βΉ997.00 Cr | β | β | 16.9% | 31.5% | 29.0% |
| Mar 2020 | βΉ2.63 K Cr | β | βΉ773.00 Cr | β | β | 21.2% | 28.8% | 71.0% |
| Mar 2019 | βΉ2.04 K Cr | β | βΉ452.00 Cr | β | β | 15.8% | 26.2% | 40.8% |
| Mar 2018 | βΉ1.62 K Cr | β | βΉ321.00 Cr | β | β | 13.3% | 9.5% | -22.5% |
| Mar 2017 | βΉ1.48 K Cr | β | βΉ414.00 Cr | β | β | 19.8% | 9.7% | 31.8% |
| Mar 2016 | βΉ1.35 K Cr | β | βΉ314.00 Cr | β | β | 18.7% | 35.6% | 50.2% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 4,154 |
| Total Expenses | 2,635 |
| EBIT / Operating Profit | 1,519 |
| OPM % | 37% |
| Other Income | 246 |
| Finance Costs | 33 |
| Depreciation & Amortisation | 175 |
| Profit Before Tax | 1,557 |
| Tax % | - |
| Net Profit / PAT | 1,156 |
| EPS (βΉ) | 70.18 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Gland Pharma Limitedthis co. | βΉ28.32 K Cr | βΉ4.12 K Cr | 24.50 | 2.82 | 17.29 | -1.2% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |